Hologic, Inc. (NASDAQ:HOLX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Hologic, Inc. (NASDAQ:HOLX) has earned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $88.92.

A number of analysts have weighed in on the company. UBS Group boosted their price target on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Monday, January 13th. Leerink Partners cut their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Finally, Morgan Stanley cut their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $71.19 on Thursday. Hologic has a fifty-two week low of $68.61 and a fifty-two week high of $84.67. The business has a 50-day moving average of $74.30 and a two-hundred day moving average of $78.31. The stock has a market capitalization of $16.07 billion, a P/E ratio of 21.38, a P/E/G ratio of 2.38 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the previous year, the firm earned $0.89 earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts predict that Hologic will post 4.27 EPS for the current fiscal year.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.88% of the company’s stock.

Institutional Investors Weigh In On Hologic

Large investors have recently modified their holdings of the stock. Wolff Wiese Magana LLC bought a new stake in shares of Hologic in the 3rd quarter valued at approximately $25,000. General Partner Inc. bought a new stake in shares of Hologic in the 4th quarter valued at approximately $26,000. Groupama Asset Managment grew its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 2,999 shares during the period. Sunbelt Securities Inc. bought a new stake in Hologic during the 2nd quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. grew its position in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.